Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2008

01-12-2008 | Case Reports

Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome

Authors: Antonio Galán Brotons, Joaquín Borrás-Blasco, J. Dolores Rosique Robles, José María Vicent Verge, Elvira Casterá

Published in: Clinical and Translational Oncology | Issue 12/2008

Login to get access
Metadata
Title
Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome
Authors
Antonio Galán Brotons
Joaquín Borrás-Blasco
J. Dolores Rosique Robles
José María Vicent Verge
Elvira Casterá
Publication date
01-12-2008
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 12/2008
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-008-0299-1

Other articles of this Issue 12/2008

Clinical and Translational Oncology 12/2008 Go to the issue

News and Views

Music therapy in oncology

Reviews

Human papillomavirus vaccine and cervical cancer prevention

Case Reports

Young male patient with bilateral synchronous testicular germ cell tumour. Considerations for partial orchiectomy

Research Articles

Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib

Educational Series

Genetically modified mouse models in cancer studies

Research Articles

Employment in a cohort of cancer patients in Spain. A predictive model of working outcomes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits